Medically reviewed by Lindsey Waldman, MD, RD A C. diff (Clostridioides difficile ) diet may help alleviate diarrhea (the ...

But in C. difficile cases, the nervous system can have a hyperactive response that becomes part of the problem, and UVA's new ...

What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Zinplava (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the FDA’s drug shortages tracker.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

In a counterintuitive move, bacteria are known to produce self-destructive toxins. However, they also make antitoxins, and researchers at Lawrence Livermore National Laboratory (LLNL) have identified ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Pfizer advances second-generation C. diff vaccine with Phase 2 data expected in 2025. Analyst maintains cautious optimism as investor sentiment remains muted on vaccine efforts. Pfizer hosted a ...

Pharmaceuticals is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...